project . 2016 - 2021 . On going

VISION DMD

VISION-DMD - Phase 2 Clinical Trials of VBP15: An Innovative Steroid-like Intervention on Duchenne Muscular Dystrophy
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 667078 Call for proposal: H2020-PHC-2015-two-stage
  • Funded under: H2020 | RIA Overall Budget: 16,858,700 EURFunder Contribution: 6,000,000 EUR
  • Status: On going
  • Start Date
    01 Jan 2016
    End Date
    31 Dec 2021
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
VISION-DMD aims to advance clinical development of the orphan drug VBP15 as a new therapy to revolutionise care for all patients with Duchenne muscular dystrophy (DMD) by 2020, in line with IRDiRC goals. DMD is an incurable, rare muscle wasting disease; boys progressively weaken, lose ambulation and death occurs by early adulthood. Corticosteroids (CS) are widely recognised to increase muscle strength and delay disease progression but global acceptance as standard of care is very variable due to severe side effects. VBP15 is an innovative steroid-like drug designed to retain or better CS efficacy and improve membrane stabilization with reduced or no side effects...
Description
VISION-DMD aims to advance clinical development of the orphan drug VBP15 as a new therapy to revolutionise care for all patients with Duchenne muscular dystrophy (DMD) by 2020, in line with IRDiRC goals. DMD is an incurable, rare muscle wasting disease; boys progressively weaken, lose ambulation and death occurs by early adulthood. Corticosteroids (CS) are widely recognised to increase muscle strength and delay disease progression but global acceptance as standard of care is very variable due to severe side effects. VBP15 is an innovative steroid-like drug designed to retain or better CS efficacy and improve membrane stabilization with reduced or no side effects...
Any information missing or wrong?Report an Issue